FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

仅供研究使用。 完整免责声明 →

肽库

FDA监管成分

该成分是FDA批准或监管的。未经有效处方购买可能违反联邦法律。请在您所在地区核实所有法律规定。

Liraglutide

Victoza / Saxenda

Weight Loss & Metabolic

Liraglutide is a GLP-1 receptor agonist developed by Novo Nordisk, sharing 97% homology with native human GLP-1. It is FDA-approved as Victoza for type 2 diabetes management and as Saxenda for chronic weight management. As a once-daily injection, it was the first long-acting GLP-1 analog to achieve widespread clinical use and served as the predecessor to semaglutide.

作用机制

GLP-1 receptor agonist with 97% homology to native GLP-1. Enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying.

研究协议

仅供研究使用,非医疗建议。

Weight management protocols use up to 3.0mg daily with weekly 0.6mg dose escalation.

研究笔记

Clinical Research Status

Liraglutide holds full FDA approval for two indications: type 2 diabetes (Victoza, approved 2010) and obesity (Saxenda, approved 2014). The LEADER cardiovascular outcomes trial demonstrated a 13% reduction in major adverse cardiovascular events. It remains widely prescribed though newer weekly agents are increasingly preferred.

Key Published Findings

The SCALE trials demonstrated 5-8% mean body weight loss versus placebo across multiple populations. Liraglutide has been shown to reduce HbA1c by 1.0-1.5% in type 2 diabetes, with additional benefits in beta-cell preservation. Post-marketing data from over a decade of use provides one of the most robust safety databases among GLP-1 agonists.

Safety Profile

The most common adverse effects are gastrointestinal: nausea, vomiting, and diarrhea, typically diminishing over 4-8 weeks of dose titration. A boxed warning exists for medullary thyroid carcinoma risk based on rodent studies, though human epidemiological data has not confirmed this risk. Pancreatitis cases have been reported rarely, and the drug is contraindicated in patients with personal or family history of MTC.

Comparison to Related Compounds

Compared to semaglutide, liraglutide requires daily rather than weekly injection and produces less weight loss (approximately 5-8% vs 15-17% body weight). It has a shorter half-life of 13 hours versus semaglutide's 7-day half-life, resulting in lower steady-state exposure. However, its longer track record provides greater long-term safety confidence for some clinicians.

Community Observations

Many users report that liraglutide's daily dosing allows more flexible appetite control timing compared to weekly injectables. The gradual dose titration schedule (0.6mg to 3.0mg over 4-5 weeks for obesity) helps mitigate GI side effects. Some practitioners still prefer it for patients who want the option to pause treatment quickly due to its shorter duration of action.

半衰期

~13 hours

复溶

Pre-filled pen (no reconstitution)

存储

冻干

Refrigerate 2-8C before first use.

复溶后

Room temperature or refrigerate. Use within 30 days.

美国法律状态

FDA-approved (Rx only)

又称作

VictozaSaxenda

常见问题

什么是 Liraglutide?

Liraglutide is a GLP-1 receptor agonist developed by Novo Nordisk, sharing 97% homology with native human GLP-1. It is FDA-approved as Victoza for type 2 diabetes management and as Saxenda for chronic weight management. As a once-daily injection, it was the first long-acting GLP-1 analog to achieve widespread clinical use and served as the predecessor to semaglutide.

Liraglutide 如何起作用?

GLP-1 receptor agonist with 97% homology to native GLP-1. Enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying.

Liraglutide 在美国的监管状态是什么?

FDA-approved (Rx only)

Liraglutide 的半衰期是多少?

~13 hours

Liraglutide 还有哪些名称?

Victoza, Saxenda

Peptide Contacts仅提供基于研究的摘要,仅供信息参考。我们不托管、分发或支持供应商文档。所有证书分析、GMP证书和供应商通信必须由买家直接请求并验证。本平台上任何内容均不构成法律、医疗或专业建议。用户在购买任何研究化学品之前应自行核实供应商资质,并确保遵守所有适用的当地、州及联邦法律法规,承担全部法律责任。

阅读完整免责声明